<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The value of high-dose chemotherapy with hematologic stem cell rescue has not yet been established in the treatment of low-grade non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>We report the results of a retrospective "France Autogreffe" study of 42 patients grafted during first partial remission (N = 13) or chemosensitive relapse (N = 29) for follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> before January 1990 </plain></SENT>
<SENT sid="2" pm="."><plain>The median age was 38 years (range: 26 to 61 years) </plain></SENT>
<SENT sid="3" pm="."><plain>Preparative therapy was chemotherapy alone in 22 patients and total body irradiation (TBI)-containing regimens in 20 patients </plain></SENT>
<SENT sid="4" pm="."><plain>Thirty-seven patients received hematopoietic marrow stem cells </plain></SENT>
<SENT sid="5" pm="."><plain>Bone marrow purging was performed in 15 patients </plain></SENT>
<SENT sid="6" pm="."><plain>Five patients received peripheral blood stem cells </plain></SENT>
<SENT sid="7" pm="."><plain>With a median follow-up of 43 months, relapse-free survival is 66%, event-free survival 58%, and overall survival 83% </plain></SENT>
<SENT sid="8" pm="."><plain>To date, no prognostic factors have been shown </plain></SENT>
<SENT sid="9" pm="."><plain>Nine of these patients were tested for evaluation of <z:e sem="disease" ids="C0242596" disease_type="Neoplastic Process" abbrv="MRD">minimal residual disease</z:e> by polymerase chain reaction analysis of bc12 rearrangement in the blood </plain></SENT>
<SENT sid="10" pm="."><plain>Six were positive </plain></SENT>
</text></document>